{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:43:39Z","timestamp":1791593019472,"version":"4.3.4"},"reference-count":44,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to describe adverse clinical and radiographic musculoskeletal findings in dogs treated with bedinvetmab (Librela).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Musculoskeletal adverse events in dogs treated with bedinvetmab were obtained from the Zoetis Global Pharmacovigilance database. Case inclusion criteria were adverse event reports that contained a minimum amount of medical information to allow for interpretation of the case along with radiographs or radiology reports. Following initial review, cases were assigned to one of the following categories: (a) insufficient information; (b) consistent with normal progression of osteoarthritis; (c) consistent with other specific orthopedic disease; or (d) atypical findings. Category (d) cases went through a second review, in which they were assigned to descriptive categories based on radiographic changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period (November 2020 through December 2025), 319 cases were considered as potential cases of adverse musculoskeletal events. Review of these cases found 186 that had atypical radiographic findings. Abnormal periarticular bone remodeling was the most common change noted, but other significant changes were found. Most commonly, the elbow or tarsus joint was involved. Changes occurred unilaterally or bilaterally and could be progressive and affect different joints in the same dog. Concurrent administration of NSAIDs was reported in 118 dogs (63%), and off-label use of bedinvetmab was reported in 46 dogs (25%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes the clinical and radiographic features seen following bedinvetmab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>Dogs can exhibit unique clinical and radiographic features when treated with bedinvetmab that can differentiate them from other musculoskeletal conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/javma.26.05.0379","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:41:33Z","timestamp":1788180093000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Atypical radiographic changes seen in dogs treated with bedinvetmab (Librela)"],"prefix":"10.2460","author":[{"given":"Steven C.","family":"Budsberg","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan N.","family":"Clements","sequence":"additional","affiliation":[{"name":"Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wennemuth","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Veterinary Clinic Hofheim, Hofheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"1","key":"ref1","series-title":"Osteoarthritis Cartilage","first-page":"16","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum F","year":"2013","unstructured":"Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16-21. doi:10.1016\/j.joca.2012.11.012"},{"issue":"5","key":"ref2","series-title":"Vet Comp Orthop Traumatol","first-page":"339","article-title":"A review of osteoarthritis and obesity: current understanding of the relationship and benefit of obesity treatment and prevention in the dog","volume":"22","author":"Marshall W","year":"2009","unstructured":"Marshall W, Bockstahler B, Hulse D, Carmichael S. A review of osteoarthritis and obesity: current understanding of the relationship and benefit of obesity treatment and prevention in the dog. Vet Comp Orthop Traumatol. 2009;22(5):339-345. doi:10.3415\/VCOT-08-08-0069"},{"issue":"2","key":"ref3","series-title":"Bone","first-page":"249","article-title":"The role of synovitis in osteoarthritis pathogenesis","volume":"51","author":"Scanzello CR","year":"2012","unstructured":"Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249-257. doi:10.1016\/j.bone.2012.02.012"},{"issue":"5-6","key":"ref4","series-title":"Ann Phys Rehabil Med","first-page":"333","article-title":"An update on the pathophysiology of osteoarthritis","volume":"59","author":"Mobasheri A","year":"2016","unstructured":"Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016;59(5-6):333-339. doi:10.1016\/j.rehab.2016.07.004"},{"issue":"2","key":"ref5","series-title":"Curr Opin Support Palliat Care","first-page":"148","article-title":"Osteoarthritis pain: recent advances and controversies","volume":"12","author":"Schaible H-G","year":"2018","unstructured":"Schaible H-G. Osteoarthritis pain: recent advances and controversies. Curr Opin Support Palliat Care. 2018;12(2):148-153. doi:10.1097\/SPC.0000000000000334"},{"key":"ref6","series-title":"Vet J","first-page":"106102","article-title":"Quantitative sensory testing in canine musculoskeletal pain: findings from a systematic review, meta-analysis feasibility assessment, and limitations","volume":"304","author":"Monteiro BP","year":"2024","unstructured":"Monteiro BP, Otis C, Nitulescu R, Troncy E. Quantitative sensory testing in canine musculoskeletal pain: findings from a systematic review, meta-analysis feasibility assessment, and limitations. Vet J. 2024;304:106102. doi:10.1016\/j.tvjl.2024.106102"},{"issue":"6","key":"ref7","series-title":"Pain","first-page":"1325","article-title":"Widespread somatosensory sensitivity in naturally occurring canine model of osteoarthritis","volume":"157","author":"Knazovicky D","year":"2016","unstructured":"Knazovicky D, Helgeson ES, Case B, Gruen ME, Maixner W, Lascelles BDX. Widespread somatosensory sensitivity in naturally occurring canine model of osteoarthritis. Pain. 2016;157(6):1325-1332. doi:10.1097\/j.pain.0000000000000521"},{"key":"ref8","series-title":"Vet J","first-page":"71","article-title":"Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017","volume":"250","author":"Lascelles BDX","year":"2019","unstructured":"Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016\/j.tvjl.2019.07.001"},{"key":"ref9","series-title":"Front Vet Sci","first-page":"1374858","article-title":"How does chronic pain impact the lives of dogs: an investigation of factors that are associated with pain using the Animal Welfare Assessment Grid","volume":"11","author":"Malkani R","year":"2024","unstructured":"Malkani R, Paramasivam S, Wolfensohn S. How does chronic pain impact the lives of dogs: an investigation of factors that are associated with pain using the Animal Welfare Assessment Grid. Front Vet Sci. 2024;11:1374858. doi:10.3389\/fvets.2024.1374858. Published correction appears in Front Vet Sci. 2024;11:1414314. doi:10.3389\/fvets.2024.1414314. Published correction appears in Front Vet Sci. 2024;11:1458084. doi:10.3389\/fvets.2024.1458084"},{"issue":"2","key":"ref10","series-title":"Animals (Basel)","first-page":"318","article-title":"Pain and problem behavior in cats and dogs","volume":"10","author":"Mills DS","year":"2020","unstructured":"Mills DS, Demontigny-B\u00e9dard I, Gruen M,  Pain and problem behavior in cats and dogs. Animals (Basel). 2020;10(2):318. doi:10.3390\/ani10020318"},{"key":"ref11","series-title":"Appl Anim Behav Sci","first-page":"105661","article-title":"Associations between osteoarthritis and duration and quality of night-time rest in dogs","volume":"253","author":"Smith M","year":"2022","unstructured":"Smith M, Mendl M, Murrell JC. Associations between osteoarthritis and duration and quality of night-time rest in dogs. Appl Anim Behav Sci. 2022;253:105661. doi:10.1016\/j.applanim.2022.105661"},{"issue":"9","key":"ref12","series-title":"PLoS One","first-page":"e0221869","article-title":"Optimising outputs from a validated online instrument to measure health-related quality of life (HRQL) in dogs","volume":"14","author":"Davies V","year":"2019","unstructured":"Davies V, Reid J, Wiseman-Orr ML, Scott EM. Optimising outputs from a validated online instrument to measure health-related quality of life (HRQL) in dogs. PLoS One. 2019;14(9):e0221869. doi:10.1371\/journal.pone.0221869"},{"issue":"2","key":"ref13","series-title":"J Am Vet Med Assoc","first-page":"209","article-title":"Causes of death or reasons for euthanasia in military working dogs: 927 cases (1993-1996)","volume":"219","author":"Moore GE","year":"2001","unstructured":"Moore GE, Burkman KD, Carter MN, Peterson MR. Causes of death or reasons for euthanasia in military working dogs: 927 cases (1993-1996). J Am Vet Med Assoc. 2001;219(2):209-214. doi:10.2460\/javma.2001.219.209"},{"issue":"1","key":"ref14","series-title":"Sci Rep","first-page":"9145","article-title":"Proportion and risk factors for death by euthanasia in dogs in the UK","volume":"11","author":"Pegram C","year":"2021","unstructured":"Pegram C, Gray C, Packer RMA,  Proportion and risk factors for death by euthanasia in dogs in the UK. Sci Rep. 2021;11(1):9145. doi:10.1038\/s41598-021-88342-0"},{"key":"ref15","series-title":"Vet J","first-page":"105868","article-title":"Relationships among owner consideration of euthanasia, caregiver burden, and treatment satisfaction in canine osteoarthritis","volume":"286","author":"Spitznagel MB","year":"2022","unstructured":"Spitznagel MB, Patrick K, Gober MW,  Relationships among owner consideration of euthanasia, caregiver burden, and treatment satisfaction in canine osteoarthritis. Vet J. 2022;286:105868. doi:10.1016\/j.tvjl.2022.105868"},{"issue":"4","key":"ref16","series-title":"J Small Anim Pract","first-page":"177","article-title":"2022 WSAVA guidelines for the recognition, assessment and treatment of pain","volume":"64","author":"Monteiro B","year":"2023","unstructured":"Monteiro B, Lascelles B, Murrell J, Robertson S, Steagall PVM, Wright B. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. J Small Anim Pract. 2023;64(4):177-254. doi:10.1111\/jsap.13566"},{"issue":"2","key":"ref17","series-title":"J Am Anim Hosp Assoc","first-page":"55","article-title":"2022 AAHA Pain Management Guidelines for Dogs and Cats","volume":"58","author":"Gruen ME","year":"2022","unstructured":"Gruen ME, Lascelles BDX, Colleran E,  2022 AAHA Pain Management Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2022;58(2):55-76. doi:10.5326\/JAAHA-MS-7292"},{"key":"ref18","series-title":"Front Vet Sci","first-page":"1137888","article-title":"COAST Development Group\u2019s international consensus guidelines for the treatment of canine osteoarthritis","volume":"10","author":"Cachon T","year":"2023","unstructured":"Cachon T, Frykman O, Innes JF,  COAST Development Group\u2019s international consensus guidelines for the treatment of canine osteoarthritis. Front Vet Sci. 2023;10:1137888. doi:10.3389\/fvets.2023.1137888"},{"key":"ref19","series-title":"Vet J","first-page":"105733","article-title":"Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs","volume":"276","author":"Krautmann M","year":"2021","unstructured":"Krautmann M, Walters R, Cole P,  Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021;276:105733. doi:10.1016\/j.tvjl.2021.105733"},{"key":"ref20","series-title":"Vet Anaesth Analg","first-page":"943","article-title":"A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis","volume":"48","author":"Corral MJ","year":"2021","unstructured":"Corral MJ, Moyaert H, Fernandes T,  A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48:943-955. doi:10.1016\/j.vaa.2021.08.001"},{"issue":"5","key":"ref21","series-title":"Vet Anaesth Analg","first-page":"446","article-title":"A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody","volume":"50","author":"Michels GM","year":"2023","unstructured":"Michels GM, Honsberger NA, Walters RR, Tena JKS, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446-458. doi:10.1016\/j.vaa.2023.06.003"},{"key":"ref22","series-title":"Front Vet Sci","first-page":"1502218","article-title":"A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis","volume":"12","author":"Innes JF","year":"2025","unstructured":"Innes JF, Lascelles BDX, Bell D,  A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218. doi:10.3389\/fvets.2025.1502218"},{"key":"ref23","series-title":"Res Sq","article-title":"A randomized, double-blinded, noninferiority trial evaluating the efficacy of bedinvetmab (Librela), a fully canine anti-nerve growth factor monoclonal antibody, compared to grapiprant for osteoarthritis pain in dogs using force plate gait analysis","author":"Enomoto M","unstructured":"Enomoto M, Buslinger L, Thonen-Fleck R,  A randomized, double-blinded, noninferiority trial evaluating the efficacy of bedinvetmab (Librela), a fully canine anti-nerve growth factor monoclonal antibody, compared to grapiprant for osteoarthritis pain in dogs using force plate gait analysis. Res Sq. Preprint posted online September 17, 2025. doi:10.21203\/rs.3.rs-7303674\/v1"},{"key":"ref24","series-title":"Front Vet Sci","first-page":"1395360","article-title":"Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study","volume":"11","author":"Reid J","year":"2024","unstructured":"Reid J, Gildea E, Davies V, Thompson J, Scott M. Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Front Vet Sci. 2024;11:1395360. doi:10.3389\/fvets.2024.1395360"},{"issue":"15","key":"ref25","series-title":"Animals (Basel)","first-page":"2231","article-title":"Use of bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns","volume":"14","author":"Gildea E","year":"2024","unstructured":"Gildea E, North C, Walker K, Adriaens F, Lascelles BDX. Use of bedinvetmab (Librela) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: quantitative analysis of veterinarian satisfaction and real-world treatment patterns. Animals (Basel). 2024;14(15):2231. doi:10.3390\/ani14152231"},{"key":"ref26","series-title":"Front Vet Sci","first-page":"1558222","article-title":"Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela)","volume":"12","author":"Monteiro BP","year":"2025","unstructured":"Monteiro BP, Simon A, Knesl O,  Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela). Front Vet Sci. 2025;12:1558222. doi:10.3389\/fvets.2025.1558222."},{"issue":"2","key":"ref27","series-title":"Vet Anaesth Analg","first-page":"263","article-title":"A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment","volume":"52","author":"Iff I","year":"2025","unstructured":"Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment. Vet Anaesth Analg. 2025;52(2):263-265. 20241129. doi:10.1016\/j.vaa.2024.11.041."},{"key":"ref28","series-title":"Front Vet Sci","first-page":"1581490","article-title":"Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)","volume":"12","author":"Farrell M","year":"2025","unstructured":"Farrell M, Waibel FWA, Carrera I,  Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. doi:10.3389\/fvets.2025.1581490"},{"issue":"2","key":"ref29","series-title":"Companion Anim","first-page":"76","article-title":"Identification and possible pathogenesis of bedinvetmab-associated adverse joint events","volume":"31","author":"Armitage A","year":"2026","unstructured":"Armitage A. Identification and possible pathogenesis of bedinvetmab-associated adverse joint events. Companion Anim. 2026;31(2):76-83. doi:10.12968\/coan.2026.0009"},{"key":"ref30","series-title":"European Medicines Agency","article-title":"Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans","author":"Committee for Veterinary Medicinal Products","year":"2026","unstructured":"Committee for Veterinary Medicinal Products. Guidance notes on the use of VeDDRA terminology for reporting suspected adverse events in animals and humans. European Medicines Agency. June 18, 2026. Accessed June 18, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-notes-use-veterinary-dictionary-drug-regulatory-activities-veddra-terminology-reporting-suspected-adverse-events-animals-humans-rev16_en.pdf"},{"issue":"7","key":"ref31","series-title":"Arthritis Rheumatol","first-page":"1167","article-title":"Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","volume":"73","author":"Hochberg MC","year":"2021","unstructured":"Hochberg MC, Carrino JA, Schnitzer TJ,  Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021;73(7):1167-1177. doi:10.1002\/art.41674"},{"key":"ref32","article-title":"Identification of adverse Librela-associated joint events","author":"Armitage A","year":"2025","unstructured":"Armitage A. Identification of adverse Librela-associated joint events. Presented at: Veterinary Osteoarthritis Alliance Congress; May 21-22, 2025; Loughborough, UK."},{"key":"ref33","article-title":"Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire","author":"Lee BT","year":"2026","unstructured":"Lee BT, Fox DB. Further characterization of a potential musculoskeletal syndrome associated with bedinvetmab in dogs: results from a surgeon questionnaire. Abstract presented at: 53rd Annual Veterinary Orthopedic Society Conference; March 14-21, 2026; Big Sky, MT."},{"issue":"1","key":"ref34","series-title":"Sci Rep","first-page":"5641","article-title":"Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care","volume":"8","author":"Anderson KL","year":"2018","unstructured":"Anderson KL, O\u2019Neill DG, Brodbelt DC,  Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8(1):5641. doi:10.1038\/s41598-018-23940-z"},{"issue":"suppl 1","key":"ref35","series-title":"Osteoarthritis Cartilage","first-page":"S18","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg MC","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(suppl 1):S18-S21. doi:10.1016\/j.joca.2014.10.005"},{"issue":"5","key":"ref36","series-title":"Pain Med","first-page":"1185","article-title":"The effectiveness of anti-nerve growth factor monoclonal antibodies in the management of pain in osteoarthritis of the hip and knee: a PRISMA systematic review and meta-analysis","volume":"22","author":"Seah KTM","year":"2021","unstructured":"Seah KTM, Rammanohar J, Sutton J, alto K, Khan WS. The effectiveness of anti-nerve growth factor monoclonal antibodies in the management of pain in osteoarthritis of the hip and knee: a PRISMA systematic review and meta-analysis. Pain Med. 2021;22(5):1185-1204. doi:10.1093\/pm\/pnaa441"},{"key":"ref37","series-title":"Bone","first-page":"117542","article-title":"The effect of celecoxib and muMab911 on strain adaptive bone remodeling and fracture repair in female mice: implications for rapidly progressive osteoarthritis","volume":"198","author":"Ruggiero N","year":"2025","unstructured":"Ruggiero N, Ciuciu A, Sedigh A,  The effect of celecoxib and muMab911 on strain adaptive bone remodeling and fracture repair in female mice: implications for rapidly progressive osteoarthritis. Bone. 2025;198:117542. doi:10.1016\/j.bone.2025.117542"},{"issue":"3","key":"ref38","series-title":"Invest New Drugs","first-page":"800","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel M","year":"2020","unstructured":"Noel M, O\u2019Reilly EM, Wolpin BM,  Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38(3):800-811. doi:10.1007\/s10637-019-00830-3"},{"issue":"7525","key":"ref39","series-title":"Nature","first-page":"130","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace L","year":"2014","unstructured":"Bonapace L, Coissieux MM, Wyckoff J,  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130-133. doi:10.1038\/nature13862"},{"issue":"1","key":"ref40","series-title":"Nat Commun","first-page":"4939","article-title":"NGF-TrkA signaling dictates neural ingrowth and aberrant osteochondral differentiation after soft tissue trauma","volume":"12","author":"Lee S","year":"2021","unstructured":"Lee S, Hwang C, Marini S,  NGF-TrkA signaling dictates neural ingrowth and aberrant osteochondral differentiation after soft tissue trauma. Nat Commun. 2021;12(1):4939. doi:10.1038\/s41467-021-25143-z"},{"issue":"11","key":"ref41","series-title":"Stem Cells Transl Med","first-page":"1165","article-title":"TrkA+ neurons induce pathologic regeneration after soft tissue trauma","volume":"11","author":"Cherief M","year":"2022","unstructured":"Cherief M, Negri S, Qin Q,  TrkA+ neurons induce pathologic regeneration after soft tissue trauma. Stem Cells Transl Med. 2022;11(11):1165-1176. doi:10.1093\/stcltm\/szac073"},{"key":"ref42","series-title":"BMJ","first-page":"g5074","article-title":"Before and after study designs","volume":"349","author":"Sedgwick P","year":"2014","unstructured":"Sedgwick P. Before and after study designs. BMJ. 2014;349:g5074. doi:10.1136\/bmj.g5074"},{"key":"ref43","series-title":"BMJ","first-page":"f7707","article-title":"Case-control studies: advantages and disadvantages","volume":"348","author":"Sedgwick P","year":"2014","unstructured":"Sedgwick P. Case-control studies: advantages and disadvantages. BMJ. 2014;348:f7707. doi:10.1136\/bmj.f7707"},{"issue":"1","key":"ref44","series-title":"Drug Saf","first-page":"19","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez E","year":"2009","unstructured":"Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19-31. doi:10.2165\/00002018-200932010-00002"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.05.0379\/javma.26.05.0379.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/aop\/javma.26.05.0379\/javma.26.05.0379.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:41:33Z","timestamp":1788180093000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.05.0379\/javma.26.05.0379.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2460\/javma.26.05.0379","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}